NEW YORK, July 26, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three months ended June 30, 2023 after the close of the U.S. financial markets on August 9, 2023 and will host a conference call beginning at 4:30 p.m. Eastern time.
Conference Call & Webcast Details
Date: | Wednesday, August 9th |
Time: | 4:30 p.m. Eastern Time |
Toll-Free Dial-In: | 1-877-704-4453 |
International Dial-In: | 1-201-389-0920 |
Conference ID: | 13739131 |
Live & Archived Webcast: | Link |
About LifeMD™
LifeMD is a 50-state direct-to-patient telehealth company with a portfolio of brands that offer virtual primary care, diagnostics, and specialized treatment for men’s and women’s health, allergy & asthma, and dermatological conditions. By leveraging its proprietary technology platform, 50-state affiliated medical group, and nationwide mail-order pharmacy network, LifeMD is increasing access to top-notch healthcare that is affordable to anyone. To learn more, go to LifeMD.com.
Media Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact
Marc Benathen, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$5.08 |
Daily Change: | -0.14 -2.68 |
Daily Volume: | 152,039 |
Market Cap: | US$220.010M |
November 07, 2024 November 06, 2024 October 23, 2024 September 19, 2024 August 07, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB